Glenmark Pharmaceuticals (GLENMARK.NS)

Executive Summary

Glenmark Pharmaceuticals is a global pharmaceutical company headquartered in Mumbai, India, with a presence in over 50 countries. The company focuses on branded and generic formulations, active pharmaceutical ingredients (APIs), and biosimilars, with key therapeutic areas including dermatology, respiratory, and oncology. Glenmark's R&D pipeline comprises 25 drug candidates, including new chemical entities and biosimilars, with several late-stage trials in asthma, psoriasis, and atopic dermatitis. The company operates multiple FDA- and EMA-approved manufacturing facilities across India, Europe, and Latin America. As a publicly traded entity on the National Stock Exchange of India (ticker: GLENMARK.NS), Glenmark continues to leverage its diversified portfolio and global footprint to drive growth. Recent completed trials and ongoing regulatory submissions position the company for potential near-term catalysts, though competitive pressures in generics and execution risks remain.

Upcoming Catalysts (preview)

• Q3 2026Regulatory decision on fluticasone propionate inhalation aerosol for bronchial asthma75% success
• Q4 2026Phase 3 data readout for calcipotriene/betamethasone dipropionate topical foam in psoriasis80% success
• Q2 2026Launch of a new generic or biosimilar in the US or EU market60% success